News

Investing.com -- Abbott Laboratories is presenting a complex case for value seekers as its dividend yield climbs to a ten-year high, reflecting a stock price weighed down by the $21 billion Exact Sciences integration and nearly $500 million in upheld legal judgments.

Abbott Laboratories (ABT) is back in focus after mixed first quarter results, a cut to its 2026 adjusted EPS outlook tied to the Exact Sciences acquisition, and a large baby formula legal verdict that raised fresh questions. See our latest analysis for Abbott Laboratories. The recent mix of weaker first quarter sentiment, the Exact Sciences related EPS guidance cut and the baby formula verdict has coincided with a sharp reset in expectations. The share price is down 15.9% over 30 days and...

This mortgage REIT generates income by originating and managing commercial real estate loans across the United States.

Blackstone Mortgage Trust originates senior commercial real estate loans globally, generating income primarily from interest and dividends.

The company combines strong device growth with an attractive valuation despite near-term headwinds.

Tandem Diabetes Care (NASDAQ:TNDM) reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product

ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

If you are wondering whether Abbott Laboratories at around US$87.01 is starting to look like value, the recent share price performance gives you plenty to weigh up. The stock has seen a 4.2% decline over the last week, a 14.6% decline over the last month, and is down 29.9% year to date and 33.7% over the last year. Over the last few months, headlines around Abbott have focused on its position in medical devices and diagnostics, alongside broader sector sentiment that has affected many large...

By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous blood glucose monitoring technology. The company said it is designed to deliver real-time glucose readings without the need for an external wearable device. “Submission of […]

Abbott Laboratories (NYSE:ABT) released new late breaking clinical data on its advanced cardiac devices, focusing on pulsed field ablation and conduction system pacing. The data highlights patient outcomes for the TactiFlex Duo Ablation Catheter, UltiSynq CSP ICD lead, and AVEIR CSP leadless pacemaker in complex heart rhythm disorders. These results add fresh detail on Abbott's electrophysiology and device pipeline beyond its recently covered AI enabled imaging approvals. For anyone...

These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.

Abbott’s business and dividend story remain intact even as the stock trades near 52‑week lows.

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it designated Michael Buckner as Chief Legal Officer, having previously served at Danaher as Vice President, Deputy General Counsel, and Chief M&A Counsel. Mr. Buckner has nearly 30 years of experience as a senior global legal executive with experience in complex transactions and regulatory environments, the […]

Abbott Laboratories (NYSE:ABT) is one of the best medical device stocks to invest in right now. Abbott Laboratories (NYSE:ABT) announced on April 28 that it received the U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. Management stated that the milestone marks a considerable step forward for the […]

April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its

Earlier this week, Abbott received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography platform that integrates high‑resolution coronary imaging with automated insights to guide stent sizing and placement in complex percutaneous coronary interventions. This positions Abbott at the forefront of AI-guided cardiovascular care, potentially making OCT a more intuitive, workflow-friendly tool for treating challenging coronary disease cases. Next, we’ll...